Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
  • Articles
  • Law Firms
  • Law Firms
  • Organizations
  • Organizations
    • DAMAGES—CHEMICAL PRODUCTS—Pa. Super.: Exxon loses appeal challenging $725 million compensatory award in gasoline-related leukemia case
    • CPSC NEWS—COMMENT CALENDAR—CPSC actions open for public comment
    • You have 1 more complimentary views available this month. Log in if you are already a customer
    • CPSC NEWS—COMMISSION PERSONNEL—CPSC names Beth Puchek chief AI officer to lead technology strategy
    • You have 1 more complimentary views available this month. Log in if you are already a customer
    • CPSC NEWS—INDUSTRIAL AND COMMERCIAL EQUIPMENT—Lithonia Lighting recalls luminaires over falling fixture hazard
    • You have 1 more complimentary views available this month. Log in if you are already a customer
    • EXPERT INSIGHTS—California Signs Nation-Leading AI Chatbot And Social Media Laws: What Businesses Need To Know
    • You have 1 more complimentary views available this month. Log in if you are already a customer
    • JURISDICTION—CHEMICAL PRODUCTS—N.D. Miss.: Toxic chemical exposure case remanded for lack of complete diversity
    • You have 1 more complimentary views available this month. Log in if you are already a customer
    • NHTSA NEWS—COMMENT CALENDAR—NHTSA actions open for public comment
    • You have 1 more complimentary views available this month. Log in if you are already a customer
    • NHTSA NEWS—MOTOR VEHICLES—Ford is recalling 102,000 vehicles due to inaccurate speedometer and tachometer displays
    • You have 1 more complimentary views available this month. Log in if you are already a customer
  • Articles
  • Articles
  • Law Firms
  • Law Firms
  • Organizations
  • Organizations

    Products Liability Law Daily Wrap Up, DAMAGES—CHEMICAL PRODUCTS—Pa. Super.: Exxon loses appeal challenging $725 million compensatory award in gasoline-related leukemia case, (Oct 22, 2026)

    Law Firms Mentioned:DLA Piper LLP | Locks Law Firm
    Organizations Mentioned:Exxon Mobil Corp.

    By Pankhuri Bhatnagar, B.A. LL.B.

    The gasoline maker failed to establish that the trial court abused its discretion in upholding the jury’s compensatory damages award or that the award violated due process.

    In an action brought against a gasoline manufacturer by a man who devel ...

    By Pankhuri Bhatnagar, B.A. LL.B.

    The gasoline maker failed to establish that the trial court abused its discretion in upholding the jury’s compensatory damages award or that the award violated due process.

    In an action brought against a gasoline manufacturer by a man who developed leukemia after occupational exposure to gasoline decades earlier, the Pennsylvania Superior Court affirmed a judgment against Exxon Mobil Corporation. The manufacturer’s claim that the $725 million compensatory damages award was excessive and unconstitutional was rejected because appellate review of an excessive verdict is deferential, and constitutional safeguards governing punitive damages do not apply to compensatory awards. The manufacturer’s allegations of juror bias and exposure to settlement information were rejected because its motion to supplement post-trial filings was untimely (Gill v. Exxon Mobil Corp., No. 2811 EDA 2024 (Pa. Super. Oct. 15, 2026)).

    Background. A man worked at a Pennsylvania service station from 1974 to 1979, pumping gasoline and repairing cars. He regularly used Mobil Oil gasoline to clean car parts without gloves or a respirator because he had not been warned that the benzene in gasoline was carcinogenic and could become airborne. In 2019, approximately 40 years after the exposure, he developed acute myeloid leukemia (AML). His treatment involved chemotherapy and a stem-cell transplant, followed by serious complications, chronic pain, a weakened immune system, diabetes, seizures, AML, and additional colorectal cancer. The illness restricted his activities, separated him from friends and family, and significantly affected his marriage. He and his wife sued Exxon Mobil Corp. and other companies, asserting negligence, strict product liability, and other claims. The jury found in the couple’s favor and awarded the husband $725 million for pain and suffering, embarrassment and humiliation, loss of enjoyment of life, and disfigurement, and the wife $500,000 for loss of consortium. The trial court later molded the verdict to include delay damages, bringing the total judgment to $815,833,561.65. Exxon sought judgment notwithstanding the verdict, a new trial, and remittitur. After the trial court denied post-trial relief, Exxon appealed.

    Excessive damages. Exxon argued that the $725 million award was disproportionate to the husband’s injuries, especially since his symptoms were common among cancer patients and he remained capable of traveling and socializing, making the awards for pain and suffering, loss of enjoyment of life, disfigurement, and embarrassment improper. Exxon argued that the trial court wrongly treated the man’s AML as a permanent injury despite remission and overstated its impact on his ability to work, since he had retired before his diagnosis and had not sought economic damages. An appellate court may reverse only if the trial court committed a controlling error of law or abused its discretion. Martin v. Evans, 711 A.2d 458, 461 (Pa. 1998). While Exxon acknowledged the abuse-of-discretion standard, it did not argue that the trial court’s decision was manifestly unreasonable, biased, prejudiced, or based on a misapplication of law. Instead, it asked this court to reassess the evidence and determine independently whether the award was excessive. That approach improperly sought to replace the jury’s assessment of the husband’s injuries and the trial court’s evaluation of the verdict with the appellate court’s own judgment. Because Exxon did not establish an abuse of discretion, the court dismissed this issue without relief.

    Constitutional challenge. Exxon next argued that the $725.5 million compensatory award was unconstitutional under the Fourteenth Amendment because the jury had allegedly imposed punitive damages. It relied on the constitutional limits on excessive punitive damages set out in State Farm Mutual Automobile Insurance Co. v. Campbell, 538 U.S. 408 (2003) to argue that the award was disproportionate to the harm, unsupported by reprehensible conduct, and far beyond any comparable penalty. Exxon also compared the award with the $500,000 settlement the couple had reached with another company, claiming that the remaining amount produced an extreme punitive-to-compensatory ratio. The court disagreed, explaining that punitive damages punish and deter wrongdoing, whereas compensatory damages redress the actual harm caused by wrongful conduct. Cooper Industries, Inc. v. Leatherman Tool Group, Inc., 532 U.S. 424, 432 (2001). There is no constitutional ceiling on compensatory damages for noneconomic injuries. The court’s instructions directed the jury to consider factors such as the severity and duration of the man’s injuries, their effect on daily activities, the nature of his treatment, and the extent of his physical and emotional suffering. They did not direct the jury to punish Exxon or assess the reprehensibility of its conduct. The trial court had also granted summary judgment to Exxon on punitive damages, so that issue was never submitted to the jury.

    Exxon offered no evidence that the jury disregarded the instructions and imposed punitive damages. The court further held that the three guideposts used to assess constitutionally excessive punitive damages were inapplicable to a compensatory award. The reprehensibility of a company’s conduct does not measure compensation for injury, particularly in strict-liability cases, where liability focuses on the defective product rather than the manufacturer’s intent. Sullivan v. Werner Co., 306 A.3d 846, 863 (Pa. 2023). Nor could Exxon use the settlement with the other company as a benchmark for calculating a constitutionally permissible award. A settlement may reflect the strength of the evidence, the parties’ assessment of litigation risk, or other considerations, and does not establish the value of the injuries attributable to Exxon. Comparable statutory penalties could not meaningfully determine the value of an individual’s pain, suffering, or loss of life’s pleasures. Compensatory damages instead depend on the harm suffered by the particular person. Accordingly, the court rejected Exxon’s constitutional challenge and dismissed the issue as meritless.

    Juror misconduct. The manufacturer presented printouts of certain website blogs showing an undisclosed bias against the company and exposure to confidential settlement information. The posts reportedly described Exxon as a villain, celebrated the verdict, and referred to a settlement offer made before trial. Exxon claimed the posts justified a new trial or, at minimum, an evidentiary hearing. It argued that the statements revealed dishonesty during jury selection and that the settlement information could have prejudiced the jury. The court found no abuse of discretion in the trial court’s refusal to accept the late supplement. The alleged posts were made after the verdict and did not themselves suggest that anything improper had occurred during the trial or jury deliberations. Because the trial court denied the untimely request to supplement the post-trial motion, Exxon’s juror-misconduct claim was waived on appeal.

    The case is No. 2811 EDA 2024.

    Judge: Kunselman, D.

    Attorneys: Andrew John DuPont (Locks Law Firm) for Paul Gill and Diane Gill. Ilana H. Eisenstein (DLA Piper LLP) for Exxon Mobil Corp.

    Companies: Exxon Mobil Corp.

    MainStory: TopStory CourtDecisions DamagesNews ChemicalNews PennsylvaniaNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use